Dual-targeting self-assembly sensitizer, preparation method, application and medicine

By using intravenous delivery technology of dual-target self-assembled sensitizers, the technology achieves targeting of tumor cell nuclei and microenvironment, solving the problems of insufficient targeting and strong tumor cell resistance in radiotherapy, improving radiotherapy efficacy and reducing side effects, and possessing chemotherapy drug carrier and CT imaging capabilities.

CN119015430APending Publication Date: 2024-11-26DONGGUAN PEOPLES HOSPITAL
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411157347.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-22
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Current radiotherapy methods suffer from problems such as poor targeting, significant damage to normal tissues, strong resistance of tumor cells to radiotherapy, and limited target of radiosensitizers, resulting in poor radiotherapy efficacy and significant side effects.

Method used

A dual-targeting self-assembly sensitizer was developed, comprising a DNA repair inhibitor, a bismuth-containing compound, a targeting ligand, and a tumor organelle targeting ligand, delivered via intravenous injection to achieve dual targeting of the tumor cell nucleus and the tumor microenvironment, thereby enhancing the efficacy of radiotherapy.

Benefits of technology

It improves the sensitivity of tumors to radiotherapy, reduces damage to normal tissues, enhances the killing effect on tumor cells, has the function of chemotherapeutic drug carrier and CT imaging, reduces the toxic side effects of chemotherapeutic drugs, and has high clinical translation prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015430A_ABST
    Figure CN119015430A_ABST
Patent Text Reader

Abstract

The invention relates to a dual-targeting self-assembly sensitizer, a preparation method, application and a drug. The dual-targeting self-assembly sensitizer comprises a DNA repair inhibitor, a bismuth-containing compound, a targeting ligand and a tumor organelle targeting ligand. The invention also provides a preparation method of the sensitizer, which comprises the following steps: respectively dissolving the bismuth-containing compound, the tumor organelle targeting ligand, the DNA repair inhibitor and the targeting ligand in an organic solvent, adding the obtained bismuth-containing solution into the tumor organelle targeting ligand solution to obtain a mixed solution, mixing and dispersing the obtained DNA repair inhibitor solution and the targeting ligand solution to obtain the sensitizer. A mixed solution is obtained; and mixing the two mixed solutions, and carrying out rotary evaporation to obtain the sensitizer. The invention also provides an application of the sensitizer in preparation of antitumor drugs. The invention further provides an anti-tumor medicine. The invention provides a novel radiotherapy sensitizer, and provides a new choice for improving the sensitivity of tumor radiotherapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of radiopharmaceuticals, and in particular to a dual-targeted self-assembly sensitizer, a preparation method, an application and a medicine. Background Art

[0002] With the continuous increase in the incidence of malignant tumors and their high mortality rates worldwide, malignant tumors have become a major challenge in the field of human health. Currently, chemotherapy, radiotherapy and surgery are the main means of treating malignant tumors. Among them, radiotherapy is widely used in the treatment of various types of tumors due to its non-invasive characteristics. During tumor radiotherapy, because X-rays have strong tissue penetration during radiotherapy, they can directly cause DNA breaks in tumor cell nuclei through high-energy ion radiation, or through the radiation of water and organic matter in tissue cells, decomposition produces a variety of reactive oxygen species, which interact with biological macromolecules, enhance DNA damage, and effectively kill tumor cells.

[0003] However, radiotherapy still faces many difficulties and challenges in practical applications. First, radiotherapy has poor targeting, resulting in inaccurate localization and diagnosis of tumor tissue. The high-energy X-rays diffused by the tumor during radiotherapy not only kill the tumor tissue, but also damage the normal tissues and structures next to the tumor tissue, thereby reducing the radiotherapy efficiency and increasing the adverse reactions related to radiotherapy. Secondly, most solid tumors are currently in a hypoxic environment, which can cause tumor cells to become resistant to radiotherapy, increase the proportion of G1 / S phase cells that are insensitive to radiotherapy, and accelerate the repair of DNA radiation damage, reducing the cell-killing effect of radiotherapy. In addition, due to the limited tolerance of the human body to radiation, the dose of a single radiotherapy is limited, further affecting the treatment effect.

[0004] At present, although the radiosensitizing drugs commonly used in clinical practice can improve the effect of radiotherapy to a certain extent, they generally have problems such as short half-life and insufficient tumor specificity. Therefore, the development of a new tumor-targeted synergistic radiosensitization strategy that can significantly improve the effect of radiotherapy and reduce radiotherapy-related toxicity has become an urgent need in the field of malignant tumor treatment.

[0005] In recent years, the application research of nanomaterials and nanotechnology in different fields has received extensive attention, especially the multifunctional nanomaterials have shown great potential in the application of tumor radiotherapy sensitizers or sensitizer carriers. Nanomaterials have good biosafety, targeting and tumor penetration and retention effect (EPR effect), which can enhance the enrichment of tumor areas, improve the lethality of tumor tissues, and reduce the damage to normal tissues around tumors.

[0006] In particular, materials containing high-Z atomic number metal elements (such as gold, silver, iodine, gallium, barium, iron, gadolinium, platinum, hafnium, bismuth or a combination thereof) can significantly improve the absorption cross section of the radiation due to their high X-ray absorption capacity, and can increase the energy of the deposited high-energy radiation, thereby further promoting the generation of free radicals, directly damaging DNA, and improving the radiotherapy effect. Hafnium oxide (HfO2) nanoparticles, such as NBTXR3, as an inorganic nanoradiotherapy sensitizer, have been approved by the FDA for clinical trials. They are mainly delivered clinically by intratumoral injection. Although this method can directly guide nanoparticles to the tumor site, ensuring a high contact rate with tumor cells, thereby maximizing the radiotherapy sensitization effect. However, this method has limitations: first, intratumoral injection requires precise injection technology and is only applicable to locally accessible solid tumors, such as head and neck cancer, liver cancer, etc., which limits its use for some deep tumors that are difficult to locate or difficult to access, such as scattered multiple tumors or deep visceral tumors. Secondly, intratumoral injection may lead to uneven distribution of nanoparticles in tumor tissue, thereby reducing the therapeutic effect.

[0007] To overcome these limitations, researchers are actively exploring other delivery methods, such as intravenous administration combined with targeted delivery technology, and enhancing the tumor targeting and tissue penetration of nanoparticles through surface modification or carrier systems. Another example is ligand modification, immune system-mediated targeted delivery, and combining biophysical stimulation (such as ultrasound and magnetic fields) to enhance the tumor penetration and retention of nanoparticles, thereby improving the targeting of nanomedicines.

[0008] In this context, radiosensitizers came into being. Existing radiosensitizers mainly reduce the absorbed dose of normal tissues by reducing the radiotherapy dose, thereby improving biosafety. However, the absorbed dose or killing effect of the tumor is difficult to meet the efficacy requirements of high-dose radiotherapy, which can easily lead to radiotherapy resistance in the tumor. Moreover, most current radiosensitizers have a single target. Therefore, it is necessary to continuously explore new radiotherapy targets and sensitization mechanisms, and develop more effective sensitizing drugs to meet clinical needs. Summary of the invention

[0009] In view of this, the purpose of the present invention is to provide a dual-targeted self-assembly sensitizer, a preparation method, an application and a drug, so as to provide a new type of radiotherapy sensitizer, thereby providing a new option for improving the sensitivity of tumor radiotherapy.

[0010] In order to achieve the above object, the technical solution adopted by the present invention is as follows:

[0011] A dual-targeted self-assembly sensitizer comprises a DNA repair inhibitor, a bismuth-containing compound, a targeting ligand and a tumor organelle targeting ligand.

[0012] Preferably, the dual-targeting self-assembly sensitizer can simultaneously target tumor cell nuclei and tumor microenvironment-specific molecules, thereby enhancing the selective accumulation of the drug.

[0013] Preferably, the specific molecule is selected from at least one of matrix metalloproteinases (MMPs), vascular endothelial growth factor (VEGF), integrins and hypoxia inducible factor (HIF-1α).

[0014] Preferably, the DNA repair inhibitor is selected from at least one of platinum drugs, platinum drug derivatives, platinum drug analogs, platinum drug isomers, platinum drug metabolites, paclitaxel drugs, paclitaxel drug derivatives, paclitaxel drug analogs, paclitaxel drug isomers, paclitaxel drug metabolites, chemotherapy drugs that act on DNA, chemotherapy drug derivatives that act on DNA, chemotherapy drug analogs that act on DNA, chemotherapy drug isomers that act on DNA, chemotherapy drug metabolites that act on DNA, small molecule DNA repair inhibitors, small molecule DNA repair inhibitor derivatives, small molecule DNA repair inhibitor analogs, small molecule DNA repair inhibitor isomers and small molecule DNA repair inhibitor metabolites.

[0015] Preferably, the targeting ligand is selected from at least one of folic acid (FA), folic acid-conjugated antibodies, folic acid-modified nanoparticles, hyaluronic acid (HA), transferrin (TRF), linear RGD peptide, cyclized RGD peptide (cRGD), polymeric RGD structure, RGD variant, monoclonal antibody (mAb), epidermal growth factor (EGF), linear NGR peptide, cyclized NGR peptide, improved NGR sequence, EGFR binding polypeptide, anti-EGFR polypeptide, chimeric peptide and fusion protein that can bind to EGFR, EGFR-targeted nanoparticles, EGFR-targeted liposomes, EGFR-targeted gold nanoparticles and EGFR-targeted quantum dots.

[0016] Preferably, the tumor organelle targeting ligand is selected from at least one of TAT, TAT derivatives, TAT fusion proteins and conjugates, mitochondrial penetrating peptides (MPPs), mitochondrial penetrating peptide derivatives, MPPs-drug conjugates, MPPs-MTS composite peptides, TAT-MTS composite peptides, PEI (polyethyleneimine), PEI derivatives, PEI-nucleic acid complexes, PLL (polylysine), PLL derivatives, PLL-nucleic acid complexes, lipid derivatives, nucleus targeting peptides and lysosome targeting peptides.

[0017] Among them, TAT is a cell-penetrating peptide.

[0018] Preferably, the bismuth-containing compound is selected from at least one of bismuth nitrate, bismuth chloride, bismuth oxide, bismuth phosphate and bismuth sulfate.

[0019] Preferably, the platinum drug is selected from at least one of cisplatin, carboplatin, oxaliplatin and nedaplatin.

[0020] Preferably, the taxane-based drug is selected from at least one of paclitaxel, albumin-bound paclitaxel, micellar paclitaxel (Genexol-PM) and docetaxel.

[0021] Preferably, the chemotherapy drug acting on DNA is selected from at least one of 5-fluorouracil (5-FU), capecitabine, gemcitabine, cytarabine and pemetrexed.

[0022] Preferably, the small molecule DNA repair inhibitor is selected from PARP inhibitors.

[0023] Preferably, the PARP inhibitor is at least one selected from Olaparib, Rucaparib, Niraparib and Talazoparib.

[0024] Preferably, the RGD variant is selected from one or both of RGDS and RGDV.

[0025] Preferably, the improved NGR sequence is selected from CNGRC.

[0026] Preferably, the EGFR-targeting nanoparticles are selected from polylactic-co-glycolic acid (PLGA) nanoparticles.

[0027] Preferably, the EGFR-targeted liposome is selected from one or both of paclitaxel and doxorubicin.

[0028] Preferably, the MPPs-MTS composite peptide is selected from one or both of the composite peptides of mitochondrial penetrating peptides (MPPs) and mitochondrial targeting sequences (MTS).

[0029] Preferably, the cell nucleus targeting peptide is selected from at least one of a nuclear localization signal (NLS) peptide and variants thereof.

[0030] Preferably, the lysosome targeting peptide is selected from at least one of a KFERQ sequence peptide and an endoplasmic reticulum targeting peptide, and the endoplasmic reticulum targeting peptide is selected from a KDEL sequence peptide.

[0031] Preferably, the mass ratio of the targeting ligand to the bismuth-containing compound is 5:1 to 20:1.

[0032] Preferably, the mass ratio of the DNA repair inhibitor to the bismuth-containing compound is 1:1 to 1:4.

[0033] Preferably, the mass ratio of the tumor organelle targeting ligand to the bismuth-containing compound is 2:1.

[0034] Preferably, the mass ratio of the targeting ligand to the bismuth-containing compound is 10:1.

[0035] Preferably, the mass ratio of the DNA repair inhibitor to the bismuth-containing compound is 1:1.

[0036] The present invention also provides a method for preparing a dual-targeted self-assembly sensitizer, comprising the following steps:

[0037] dispersing a bismuth-containing compound in an organic solvent to obtain a bismuth-containing solution;

[0038] dissolving the tumor organelle targeting ligand in an organic solvent to obtain a tumor organelle targeting ligand solution;

[0039] dissolving a DNA repair inhibitor in an organic solvent to obtain a DNA repair inhibitor solution;

[0040] dissolving the targeting ligand in an organic solvent to obtain a targeting ligand solution;

[0041] The bismuth-containing solution is added to the tumor organelle targeting ligand solution to obtain a tumor organelle targeting ligand@bismuth-containing compound nanosheet solution;

[0042] mixing and dispersing the DNA repair inhibitor solution and the targeting ligand solution to obtain a DNA repair inhibitor-targeting ligand compound solution;

[0043] The DNA repair inhibitor-targeting ligand compound solution is added into the tumor organelle targeting ligand@bismuth-containing compound nanosheet solution, mixed and dispersed, and rotary evaporated to obtain the tumor organelle targeting ligand-bismuth-containing compound@DNA repair inhibitor-targeting ligand compound.

[0044] Preferably, the preparation method of the dual-targeting self-assembly sensitizer comprises the following steps:

[0045] Step 1: First, chloroform and methanol are ultrasonically mixed in a mass ratio of 3:1 to form an organic solvent;

[0046] Step 2: Disperse Bi2O3 powder (2 mg of bismuth oxide) in anhydrous ethanol (2 mL), and disperse under low-frequency ultrasonic conditions for 1 h in an ice bath to obtain a solution of bismuth oxide with a concentration of 1 mg / mL;

[0047] Step 3: dissolving two hydrophobic polymers, DSPE-PEG-RGD (4 mg) and DSPE-PEG-PEI (8 mg), in an organic solvent of chloroform and methanol (the volume ratio of chloroform: methanol is 3:1) to obtain a polymer solution with good solubility;

[0048] Step 4: dissolving paclitaxel powder in an organic solvent of chloroform and methanol (the volume ratio of chloroform to methanol is 3:1), dissolving under low-frequency ultrasound for 3 minutes under ice bath conditions, and preparing a solution with a concentration of 2.4 mg / mL;

[0049] Step 5: Dissolve nintedanib powder in an organic solvent of chloroform and methanol (the volume ratio of chloroform to methanol is 3:1), dissolve under low-frequency ultrasound for 3 minutes under ice bath conditions, and prepare a solution with a concentration of 2.4 mg / mL;

[0050] Step 6: Take 1 mL of the solution obtained in step 2 and drop it into the polymer solution in step 3 to obtain RGD-PEI@Bi2O3 nanoparticles;

[0051] Step 7: The solution prepared in step 4 and the solution prepared in step 5 are mixed and dispersed by low-frequency ultrasound in an ice bath for 5 minutes to obtain a PTX-ND compound solution;

[0052] Step 8: Gradually drip the PTX-ND compound solution obtained in step 7 into the RGD-PEI@Bi2O3 nanoparticles obtained in step 6, first disperse them by low-frequency ultrasound under ice bath conditions for 30 minutes, and then obtain GRD-PEI-Bi2O3@PTX-ND nanoflakes (abbreviated as BTN) by rotary evaporation.

[0053] Step 9: The GRD-PEI-Bi2O3@PTX-ND nanosheets obtained in step 8 were hydrated in PBS (phosphate solution) at room temperature for 1 hour to finally obtain a GRD-PEI-Bi2O3@PTX-ND nanosheet solution, i.e., a sensitizer, which was freeze-dried for later use.

[0054] Preferably, the preparation of the RGD-PEI@Bi2O3 is to completely dissolve two hydrophobic polymers, DSPE-PEG-RGD (4 mg) and DSPE-PEG-PEI (8 mg), in an organic solvent of chloroform and methanol (chloroform: methanol = 3:1) to obtain an RGD-PEI@Bi2O3 polymer solution, and then gradually add the completely dissolved PTX and ND to the aforementioned RGD-PEI@Bi2O3 polymer solution, hydrate at room temperature for 1 hour, and obtain a GRD-PEI-Bi2O3@PTX-ND nanosheet suspension.

[0055] Preferably, the mass ratio of RGD-PEI to Bi2O3 is 5:1 to 20:1.

[0056] Preferably, the mass ratio of RGD-PEI to Bi2O3 is 10:1.

[0057] Preferably, the mass ratio of paclitaxel (PTX) to nintedanib (ND) is 1 / 1000 to 1 / 10000 of the total mass of the complex. Exceeding the above range will increase cell biological toxicity and reduce safety.

[0058] Preferably, the organic solvent is selected from at least one of an alcohol organic solvent, a halogenated hydrocarbon organic solvent, an ester organic solvent and an alkane organic solvent.

[0059] Preferably, the lipid derivative is phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, distearoylphosphatidylethanolamine, DSPE-PEG (polyethylene glycol modified distearoylphosphatidylethanolamine), DSPE-PEG-RGD (arginine-glycine-aspartic acid modified DSPE-PEG), DSPE-PEG-PEI (polyethyleneimine modified DSPE-PEG), and cholesterol.

[0060] Preferably, the lipid derivative is selected from DSPE-PEG-RGD and DSPE-PEG-PEI in a mass ratio of 1:2.

[0061] Preferably, the alcohol organic solvent is selected from at least one of methanol, ethanol, isopropanol and butanol.

[0062] Preferably, the halogenated hydrocarbon organic solvent is at least one selected from chloroform, dichloromethane and carbon tetrachloride.

[0063] Preferably, the ester organic solvent is selected from at least one of ethyl acetate, ethyl butyrate and ethyl formate.

[0064] Preferably, the alkane organic solvent is selected from at least one of n-hexane, cyclohexane and petroleum ether.

[0065] Preferably, the organic solvent is selected from a mixed organic solvent of chloroform and methanol in a volume ratio of 3:1.

[0066] The present invention also provides an application of a dual-targeted self-assembly sensitizer, and the application of the dual-targeted self-assembly sensitizer in the preparation of anti-tumor drugs.

[0067] Preferably, the tumor is at least one of esophageal cancer, human melanoma, non-small cell lung cancer, human cervical cancer, breast cancer, nasopharyngeal carcinoma and brain glioma.

[0068] The present invention also provides an anti-tumor drug, comprising the dual-targeting self-assembly sensitizer as described in the present invention and pharmaceutically acceptable auxiliary components.

[0069] Beneficial effects of the present invention:

[0070] The multifunctional dual-targeted self-assembled bismuth oxide radiotherapy sensitizer of the present invention can be used as a radiotherapy sensitizer and a radiation dose enhancer, and has excellent CT imaging performance, can trace drug biodistribution in real time in vivo, can also accurately target tumor cell membranes and further target subcellular structures, enhance tumor cell killing effects and inhibit DNA repair, achieve radiotherapy sensitization effects, and also has the functions of chemotherapy drug carrier, nitric oxide (NO) donor, targeted drug, etc.; at the same time, the dual-targeted self-assembled bismuth oxide radiotherapy sensitizer can be used as an excellent radiotherapy sensitizer to effectively enhance the killing of tumor cells by high-energy rays, solve the problem of radiotherapy failure caused by the limitation of normal tissue tolerance dose in clinical practice, and innovatively propose to enhance the sensitivity of tumors to radiotherapy through dual-targeted self-assembled bismuth oxide radiotherapy sensitizer, which has a high prospect of clinical transformation.

[0071] The invention discloses an intravenously injectable dual-targeted self-assembled bismuth oxide radiosensitizer drug, which is a nanoparticle material loaded with paclitaxel and nintedanib nanoparticles and a component that inhibits DNA damage repair. The physical properties of the Bi2O3 metal material bismuth are utilized to improve the sensitivity of radiotherapy and inhibit radiotherapy resistance. The material's advantages in CT imaging and its ability to catalyze hydrogen peroxide to produce oxygen are utilized to achieve an anti-tumor effect of enhanced radiosensitization.

[0072] The present invention also provides a method for preparing a dual-targeted self-assembled bismuth oxide radiotherapy sensitizer drug and its application in anti-tumor treatment. The dual-targeted self-assembled bismuth oxide radiotherapy sensitizer drug of the present invention has the effect of radiotherapy sensitization, and has the advantages of relatively low cost, simple preparation process, good biocompatibility and large loading capacity; it can reduce the toxic and side effects of chemotherapy drugs and nano drugs, and improve the sensitization effect; it can release nintedanib elements to achieve tumor microenvironment immune regulation, control inflammation, reduce the aggregation of macrophages, etc., significantly enhance the infiltration of killer T cells in the tumor lesion area, and slowly release paclitaxel drugs, further block DNA damage response signal conduction, and reduce its repair ability. It has promotion and application value in the field of radiopharmaceutical technology. BRIEF DESCRIPTION OF THE DRAWINGS

[0073] Figure 1 middle, Figure 1 A is the electron microscope image of Bi2O3; Figure 1 B is the electron microscope image of GRD-PEI-Bi2O3@PTX-ND(BTN); Figure 1 C is the particle size diagram of GRD-PEI@Bi2O3, GRD-PEI-Bi2O3@PTX, GRD-PEI-Bi2O3@ND and GRD-PEI-Bi2O3@PTX-ND; Figure 1D is the Zeta potential diagram of GRD-PEI-Bi2O3 and GRD-PEI-Bi2O3@PTX-ND; Figure 1 E is the XRD pattern of GRD-PEI-Bi2O3@PTX-ND;

[0074] Figure 2 The CT imaging results of GRD-PEI-Bi2O3@PTX-ND with different concentrations; Figure 2 A: As the drug concentration increases, the corresponding CT value becomes higher, indicating that GRD-PEI-Bi2O3@PTX-ND has the function of CT contrast agent; Figure 2 B is Figure 2 Quantization graph of A;

[0075] Figure 3 The ability of GRD-PEI-Bi2O3@PTX-ND to catalyze hydrogen peroxide to produce oxygen;

[0076] Figure 4 This is the result of uptake in the nucleus of rhodamine-encapsulated GRD-PEI-Bi2O3@PTX-ND after co-culture with A549 cells for 4 hours;

[0077] Figure 5 AD are the relative cell survival rates of A549 cells after co-culture with different concentrations of GRD-PEI-Bi2O3, GRD-PEI-Bi2O3@PTX, GRD-PEI-Bi2O3@ND, and GRD-PEI-Bi2O3@PTX-ND for 24 and 48 hours;

[0078] Figure 6 The relative survival rates of A549 cells after X-ray irradiation of 0Gy, 2Gy, 4Gy, and 6Gy with different concentrations of GRD-PEI-Bi2O3@PTX-ND and PBS;

[0079] Figure 7 This is a plate cloning experiment of A549 cells with or without X-ray irradiation using PBS and GRD-PEI-Bi2O3@PTX-ND;

[0080] Figure 8 The ROS production of A549 cells under PBS and GRD-PEI-Bi2O3@PTX-ND with or without X-ray irradiation;

[0081] Fig. 9 The apoptosis of A549 cells under PBS and GRD-PEI-Bi2O3@PTX-ND with or without X-ray irradiation;

[0082] Fig.10The foci of γH2AX produced by A549 cells under PBS and GRD-PEI-Bi2O3@PTX-ND with or without X-ray irradiation. DETAILED DESCRIPTION

[0083] The following will describe the embodiments of the present invention with reference to the preferred embodiments, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention. It should be understood that the preferred embodiments are only for illustrating the present invention, not for limiting the scope of protection of the present invention.

[0084] The present invention intends to disclose a dual-targeted self-assembly sensitizer, a preparation method, an application and a medicine, so as to provide a novel radiotherapy sensitizer, thereby providing a new option for improving the sensitivity of tumor radiotherapy.

[0085] Among them, a dual-targeted self-assembly sensitizer includes a DNA repair inhibitor, a bismuth-containing compound, a targeting ligand and a tumor organelle targeting ligand.

[0086] In some embodiments, the dual-targeted self-assembling sensitizer can simultaneously target tumor cell nuclei and tumor microenvironment-specific molecules, thereby enhancing the selective accumulation of the drug.

[0087] In some embodiments, the specific molecule is selected from at least one of matrix metalloproteinases (MMPs), vascular endothelial growth factor (VEGF), integrins, and hypoxia inducible factor (HIF-1α).

[0088] In some embodiments, the DNA repair inhibitor is selected from at least one of platinum drugs, platinum drug derivatives, platinum drug analogs, platinum drug isomers, platinum drug metabolites, paclitaxel drugs, paclitaxel drug derivatives, paclitaxel drug analogs, paclitaxel drug isomers, paclitaxel drug metabolites, chemotherapy drugs that act on DNA, chemotherapy drug derivatives that act on DNA, chemotherapy drug analogs that act on DNA, chemotherapy drug isomers that act on DNA, chemotherapy drug metabolites that act on DNA, small molecule DNA repair inhibitors, small molecule DNA repair inhibitor derivatives, small molecule DNA repair inhibitor analogs, small molecule DNA repair inhibitor isomers and small molecule DNA repair inhibitor metabolites.

[0089] In some embodiments, the targeting ligand is selected from at least one of folic acid (FA), folic acid-conjugated antibodies, folic acid-modified nanoparticles, hyaluronic acid (HA), transferrin (TRF), linear RGD peptides, cyclized RGD peptides (cRGD), polymeric RGD structures, RGD variants (such as RGDS, RGDV) and their analogs and derivatives, monoclonal antibodies (mAb), epidermal growth factor (EGF), linear NGR peptides, cyclized NGR peptides, modified NGR sequences (such as CNGRC), NGR derivatives bound to other functional molecules, EGFR-binding polypeptides, anti-EGFR polypeptides, chimeric peptides and fusion proteins that can bind to EGFR, EGFR-targeted nanoparticles, EGFR-targeted liposomes, EGFR-targeted gold nanoparticles and EGFR-targeted quantum dots.

[0090] In some embodiments, the tumor organelle targeting ligand is selected from at least one of TAT, TAT derivatives, TAT fusion proteins and conjugates, mitochondrial penetrating peptides (MPPs), mitochondrial penetrating peptide derivatives, MPPs-drug conjugates, MPPs-MTS complex peptides, TAT-MTS complex peptides, PEI (polyethyleneimine), PEI derivatives, PEI-nucleic acid complexes, PLL (polylysine), PLL derivatives, PLL-nucleic acid complexes, lipid derivatives, nucleus targeting peptides and lysosome targeting peptides.

[0091] In some embodiments, the bismuth-containing compound is selected from at least one of bismuth nitrate, bismuth chloride, bismuth oxide, bismuth phosphate, and bismuth sulfate.

[0092] In some embodiments, the platinum drug is selected from at least one of cisplatin, carboplatin, oxaliplatin and nedaplatin.

[0093] In some embodiments, the taxane drug is selected from at least one of paclitaxel, albumin-bound paclitaxel, micellar paclitaxel (Genexol-PM) and docetaxel.

[0094] In some embodiments, the chemotherapy drug acting on DNA is selected from at least one of 5-FU, Capecitabine, Gemcitabine, Cytarabine, Pemetrexed and their derivatives.

[0095] In some embodiments, the small molecule DNA repair inhibitor is selected from PARP inhibitors.

[0096] In some embodiments, the PARP inhibitor is selected from at least one of Olaparib, Rucaparib, Niraparib, and Talazoparib.

[0097] Exemplarily, the RGD variant is selected from one or both of RGDS and RGDV.

[0098] Exemplarily, the improved NGR sequence is selected from CNGRC.

[0099] Exemplarily, the EGFR-targeting nanoparticles are selected from polylactic-co-glycolic acid (PLGA) nanoparticles.

[0100] Exemplarily, the EGFR-targeted liposome is selected from one or both of paclitaxel and doxorubicin.

[0101] In some embodiments, the MPPs-MTS composite peptide is selected from one or both of a mitochondrial penetrating peptide (MPPs) and a mitochondrial targeting sequence (MTS) composite peptide.

[0102] In some embodiments, the nucleus targeting peptide is selected from at least one of a nuclear localization signal (NLS) peptide and variants thereof.

[0103] In some embodiments, the lysosome targeting peptide is selected from at least one of a KFERQ sequence peptide and an endoplasmic reticulum targeting peptide, and the endoplasmic reticulum targeting peptide is selected from a KDEL sequence peptide.

[0104] In some embodiments, the mass ratio of the targeting ligand to the bismuth-containing compound is 5:1 to 20:1.

[0105] In some embodiments, the mass ratio of the DNA repair inhibitor to the bismuth-containing compound is 1:1 to 1:4.

[0106] In some embodiments, the mass ratio of the tumor organelle targeting ligand to the bismuth-containing compound is 2:1.

[0107] Exemplarily, the mass ratio of the targeting ligand to the bismuth-containing compound is 10:1.

[0108] Exemplarily, the mass ratio of the DNA repair inhibitor to the bismuth-containing compound is 1:1.

[0109] In some embodiments, a method for preparing a dual-targeted self-assembly sensitizer is also provided, comprising the following steps:

[0110] dispersing a bismuth-containing compound in an organic solvent to obtain a bismuth-containing solution;

[0111] dissolving the tumor organelle targeting ligand in an organic solvent to obtain a tumor organelle targeting ligand solution;

[0112] dissolving a DNA repair inhibitor in an organic solvent to obtain a DNA repair inhibitor solution;

[0113] dissolving the targeting ligand in an organic solvent to obtain a targeting ligand solution;

[0114] The bismuth-containing solution is added to the tumor organelle targeting ligand solution to obtain a tumor organelle targeting ligand@bismuth-containing compound nanosheet solution;

[0115] mixing and dispersing the DNA repair inhibitor solution and the targeting ligand solution to obtain a DNA repair inhibitor-targeting ligand compound solution;

[0116] The DNA repair inhibitor-targeting ligand compound solution is added into the tumor organelle targeting ligand@bismuth-containing compound nanosheet solution, mixed and dispersed, and rotary evaporated to obtain the tumor organelle targeting ligand-bismuth-containing compound@DNA repair inhibitor-targeting ligand compound.

[0117] An exemplary method for preparing a dual-targeted self-assembly sensitizer comprises the following steps:

[0118] Step 1: First, chloroform and methanol are ultrasonically mixed in a mass ratio of 3:1 to form an organic solvent;

[0119] Step 2: Disperse Bi2O3 powder (2 mg of bismuth oxide) in anhydrous ethanol (2 mL), and disperse under low-frequency ultrasonic conditions for 1 h in an ice bath to obtain a solution of bismuth oxide with a concentration of 1 mg / mL;

[0120] Step 3: dissolving two hydrophobic polymers, DSPE-PEG-RGD (4 mg) and DSPE-PEG-PEI (8 mg), in an organic solvent of chloroform and methanol (the volume ratio of chloroform: methanol is 3:1) to obtain a polymer solution with good solubility;

[0121] Step 4: dissolving paclitaxel powder in an organic solvent of chloroform and methanol (the volume ratio of chloroform to methanol is 3:1), dissolving under low-frequency ultrasound for 3 min under ice bath conditions, and preparing a solution with a concentration of 2.4 mg / mL;

[0122] Step 5: Dissolve nintedanib powder in an organic solvent of chloroform and methanol (the volume ratio of chloroform to methanol is 3:1), dissolve under low-frequency ultrasound for 3 minutes under ice bath conditions, and prepare a solution with a concentration of 2.4 mg / mL;

[0123] Step 6: Take 1 mL of the solution obtained in step 2 and drop it into the polymer solution in step 3 to obtain RGD-PEI@Bi2O3 nanoparticles;

[0124] Step 7: The solution prepared in step 4 and the solution prepared in step 5 are mixed and dispersed by low-frequency ultrasound in an ice bath for 5 minutes to obtain a PTX-ND compound solution;

[0125] Step 8: Gradually drip the PTX-ND compound solution obtained in step 7 into the RGD-PEI@Bi2O3 nanoparticles obtained in step 6, first disperse them by low-frequency ultrasound under ice bath conditions for 30 minutes, and then obtain GRD-PEI-Bi2O3@PTX-ND nanosheets by rotary evaporation.

[0126] Step 9: The GRD-PEI-Bi2O3@PTX-ND nanosheets obtained in step 8 were hydrated in PBS (phosphate solution) at room temperature for 1 hour to finally obtain a GRD-PEI-Bi2O3@PTX-ND nanosheet solution, which was freeze-dried for later use.

[0127] Preferably, the preparation of the RGD-PEI@Bi2O3 is to completely dissolve two hydrophobic polymers, DSPE-PEG-RGD (4 mg) and DSPE-PEG-PEI (8 mg), in an organic solvent of chloroform and methanol (chloroform: methanol = 3:1) to obtain an RGD-PEI@Bi2O3 polymer solution, and then gradually add the completely dissolved PTX and ND to the aforementioned RGD-PEI@Bi2O3 polymer solution, hydrate at room temperature for 1 hour, and obtain a GRD-PEI-Bi2O3@PTX-ND nanosheet suspension.

[0128] In some embodiments, the mass ratio of RGD-PEI to Bi2O3 is 5:1 to 20:1.

[0129] In some embodiments, the mass ratio of RGD-PEI to Bi2O3 is 10:1.

[0130] In some embodiments, the mass ratio of paclitaxel (PTX) to nintedanib (ND) is 1 / 1000 to 1 / 10000 of the total mass of the complex. Exceeding the aforementioned range will increase cell biological toxicity and reduce safety.

[0131] In some embodiments, the organic solvent is selected from at least one of an alcohol organic solvent, a halogenated hydrocarbon organic solvent, an ester organic solvent, and an alkane organic solvent.

[0132] In some embodiments, the lipid derivative is at least one of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, distearoylphosphatidylethanolamine, DSPE-PEG (polyethylene glycol-modified distearoylphosphatidylethanolamine), DSPE-PEG-RGD (arginine-glycine-aspartic acid-modified DSPE-PEG), DSPE-PEG-PEI (polyethyleneimine-modified DSPE-PEG) and cholesterol.

[0133] Preferably, the lipid derivative is selected from DSPE-PEG-RGD and DSPE-PEG-PEI in a mass ratio of 1:2.

[0134] In some embodiments, the alcohol organic solvent is selected from at least one of methanol, ethanol, isopropanol and butanol.

[0135] In some embodiments, the halogenated hydrocarbon organic solvent is selected from at least one of chloroform, dichloromethane and carbon tetrachloride.

[0136] In some embodiments, the ester organic solvent is selected from at least one of ethyl acetate, ethyl butyrate and ethyl formate.

[0137] In some embodiments, the alkane organic solvent is selected from at least one of n-hexane, cyclohexane and petroleum ether.

[0138] In some embodiments, the organic solvent is selected from a mixed organic solvent of chloroform and methanol in a volume ratio of 3:1.

[0139] In some embodiments, a use of a dual-targeting self-assembling sensitizer is also provided, wherein the dual-targeting self-assembling sensitizer is used in the preparation of an anti-tumor drug.

[0140] In some embodiments, the tumor is at least one of esophageal cancer, human melanoma, non-small cell lung cancer, human cervical cancer, breast cancer, nasopharyngeal carcinoma, and brain glioma.

[0141] In some embodiments, an anti-tumor drug is also provided, comprising the dual-targeting self-assembly sensitizer in any of the above embodiments and a pharmaceutically acceptable auxiliary component.

[0142] In order to make the technical problems, technical solutions and beneficial effects solved by the present application clearer, the preparation method of the dual-target self-assembly sensitizer of the present invention will be further described in detail below in conjunction with specific embodiments and drawings. Obviously, the specific embodiments described are only a part of the embodiments of the present application, rather than all of the embodiments. The following description of at least one exemplary embodiment is actually only illustrative and is by no means intended to limit the present application and its application. Based on the specific embodiments in the present application, all other embodiments obtained by ordinary technicians in the art without paying creative work belong to the scope of protection of the present application.

[0143] If no specific techniques or conditions are specified in the specific embodiments, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.

[0144] The product of the present invention comprises four components, namely, a DNA repair inhibitor, a bismuth-containing compound, a targeting ligand or polypeptide, a tumor organelle targeting ligand or a penetrating peptide. Among them, the auxiliary sensitization component is selected from Bi2O3 in one embodiment of the present invention. In another embodiment of the present invention, the component for inhibiting DNA damage repair is selected from paclitaxel, and the component for inhibiting inflammation and anti-fibrosis is selected from nintedanib. The targeting ligand component is selected from GSPE-PEG-RGD. The tumor organelle targeting ligand is selected from DSPE-PEG-PEI.

[0145] The sources of the main materials and reagents used in the following examples are as follows:

[0146] Bismuth oxide (Bi2O3), chloroform (CHCl3) and methanol (CH3OH) were purchased from Aladdin, anhydrous ethanol, paclitaxel and nintedanib powder were purchased from MedChemExpress, and DSPE-PEG-RGD molecular weight 1000 and DSPE-PEG-PEI 2000 were purchased from Sigma-Aldrich.

[0147] Example 1

[0148] The preparation method of RGD-PEI@Bi2O3 nanosheets comprises the following steps:

[0149] The Bi2O3 powder was dispersed in anhydrous ethanol and dispersed by low-frequency ultrasound under ice bath conditions for 1 h to obtain a solution with a concentration of 1 mg / mL;

[0150] The two hydrophobic polymers DSPE-PEG-RGD and DSPE-PEG-PEI were completely dissolved in the organic solvents of chloroform and methanol (chloroform: methanol = 3:1), and then the Bi2O3 solution was added to the above organic solvent to obtain RGD-PEI@Bi2O3 nanosheets;

[0151] S1. Add 2 mg Bi2O3 powder into 2 mL anhydrous ethanol solution and disperse it by low-frequency ultrasonication for 1 h under ice bath condition to completely dissolve Bi2O3 to obtain 1 mg / mL Bi2O3 solution;

[0152] S2. Two hydrophobic polymers, DSPE-PEG-RGD (4 mg) and DSPE-PEG-PEI (8 mg), were completely dissolved in a mixed organic solvent of chloroform and methanol at a mass ratio of 1:2 (the mass ratio of chloroform: methanol was 3:1). After they were fully dissolved, 1 mL of Bi2O3 solution was added to the above organic solvent to obtain RGD-PEI@Bi2O3 nanosheets.

[0153] The particle size distribution of RGD-PEI@Bi2O3 is shown in Figure 1 As shown in C.

[0154] Example 2

[0155] The preparation method of the GRD-PEI-Bi2O3@PTX-ND-based radiotherapy sensitizer comprises the following steps:

[0156] (1) Dissolve 2.4 mg of paclitaxel powder in 1 mL of a mixed organic solvent of chloroform and methanol (chloroform: methanol = 3:1), and dissolve under low-frequency ultrasound for 3 min under ice bath conditions to prepare a solution with a concentration of 2.4 mg / mL;

[0157] (2) Dissolve 2.4 mg of nintedanib powder in 1 mL of an organic solvent of chloroform and methanol (chloroform: methanol = 3:1), and dissolve under low-frequency ultrasound for 3 min under ice bath conditions to prepare a solution with a concentration of 2.4 mg / mL;

[0158] (3) 1 mL of each of the paclitaxel and nintedanib solutions obtained in steps (1) and (2) was added dropwise to 3 mL of the RGD-PEI@Bi2O3 solution prepared in Example 1, and low-frequency ultrasonic mixing and dispersion was performed for 30 min under ice bath conditions to obtain a GRD-PEI-Bi2O3@PTX-ND solution.

[0159] (4) removing the organic solvent from the solution obtained in step (3) by rotary evaporation;

[0160] (5) After the step (4) was evaporated to dryness, 4 mL of PBS (phosphate solution) was added and hydrated at room temperature for 1 h to finally obtain a GRD-PEI-Bi2O3@PTX-ND suspension, which was freeze-dried for later use.

[0161] The prepared Bi2O3-based materials loaded with paclitaxel and nintedanib, such as Figure 1 The size of Bi2O3 shown in A is about 50nm. Figure 1 The electron microscopy image of GRD-PEI-Bi2O3@PTX-ND shown in B shows that Bi2O3 is encapsulated.

[0162] Figure 1 As shown in Figure C, the particle size distribution of GRD-PEI-Bi2O3, GRD-PEI-Bi2O3@PTX, GRD-PEI-Bi2O3@ND, and GRD-PEI-Bi2O3@PTX-ND is around 180-200nm, indicating that the preparation is successful.

[0163] The potential analysis of GRD-PEI-Bi2O3 and GRD-PEI-Bi2O3@PTX-ND is shown in Figure 1D, with a potential of -4 mV.

[0164] XRD patterns of GRD-PEI-Bi2O3@PTX-ND Figure 1 As shown in E, the Bi4f characteristic peak can be seen.

[0165] Detection and analysis

[0166] Evaluation of CT contrast effect of GRD-PEI-Bi2O3@PTX-ND nanomaterials

[0167] Bismuth-based nanomaterials with different drug concentrations were prepared and irradiated with CT. The curve was drawn according to the HU value. The results are as follows: Figure 2 shown.

[0168] from Figure 2 From the slope of the standardized curve of the HU value in , it can be seen that with the increase of drug concentration, the bismuth-based nanomaterial has an imaging enhancement effect, indicating that the bismuth-based nanomaterial of the present invention has a good imaging effect.

[0169] The ability of GRD-PEI-Bi2O3@PTX-ND nanomaterials to catalyze the production of oxygen from hydrogen peroxide

[0170] Catalase is an enzyme widely present in organisms that catalyzes the conversion of endogenous H2O2 into water and oxygen, thereby enhancing tumor oxygenation. In order to verify whether nanoparticles can be used as oxygen nanosuppliers, GRD-PEI-Bi2O3@PTX-ND nanoparticles (200ug / mL) were added to PBS solutions with different concentrations of H2O2 and divided into three groups, PBS+H2O2 (500uM), BTN+H2O2 (500uM), and BTN+H2O2 (1mM), and a portable dissolved oxygen meter (JPBI-608, China) was used to monitor oxygen levels. The results are shown in Figure 2. Figure 3 shown.

[0171] Figure 3 The results showed that bismuth-based nanomaterials have the ability to catalyze hydrogen peroxide to produce oxygen, and the level of enhanced dissolved oxygen is positively correlated with the H2O2 concentration, reflecting that the generation of O2 depends on the H2O2 concentration.

[0172] GRD-PEI-Bi2O3@PTX-ND uptake

[0173] After GRD-PEI-Bi2O3@PTX-ND was loaded with rhodamine (concentration 1 mg / mL), the uptake of the cell nucleus after co-culture with A549 cells for 4 hours was shown in the following figure. Figure 4 shown.

[0174] from Figure 4 From the analysis, we can see that compared with empty rhodamine, rhodamine loaded with GRD-PEI-Bi2O3@PTX-ND can be endocytosed and enter the cell nucleus, actively targeting the tumor cell nucleus. High-energy Auger electrons can kill the tumor DNA nucleus at close range, achieving the radiotherapy sensitization effect.

[0175] Evaluation of the biosafety of GRD-PEI-Bi2O3@PTX-ND by CCK-8 assay

[0176] When A549 cells (purchased from ATCC Cell Bank, USA) were in the logarithmic growth phase, the cells at the bottom of the culture dish were digested with trypsin, centrifuged and resuspended to make a cell suspension. The cells were counted using a cell counting plate, with a concentration of 2×10 3 The cells were plated into a 96-well plate at a density of 100 cells / well and incubated in an incubator at 37°C and 5% CO2 for 24 hours. Then, different concentrations (0, 0.05, 0.1, 0.2, 0.4, 0.8, 1.6ug / mL) of nanoparticles were added and cultured for 24 hours or 48 hours. After 24 or 48 hours, the 96-well plate was removed, the original culture medium was discarded, and 100μL of culture medium containing CCK-8 reagent was added to each well (the volume ratio of CCK-8 reagent to RPMI 1640 culture medium was 1:9), and then the plate was placed in the incubator for 2-4 hours. Finally, the absorbance of each group at 450nm was detected by an enzyme marker. The cell survival rate was calculated according to the formula: survival rate = (experimental group-blank control group) / (negative control group-blank control group)×100%, and the obtained data were plotted using Excel 2013 and GraphPadPrismV8.0 software. The results are shown in Figure 2. Figure 5 shown.

[0177] Figure 5 The graphs in the middle show the relative survival rates of cells after co-culture of GRD-PEI-Bi2O3(5A), GRD-PEI-Bi2O3@PTX(5B), GRD-PEI-Bi2O3@ND(5C), and GRD-PEI-Bi2O3@PTX-ND(5D) with A549 for 24 and 48 hours.

[0178] from Figure 5 It can be seen that bismuth-based nanosensitizer drugs have no obvious toxic side effects on cells and have good biological safety.

[0179] CCK-8 assay evaluates the inhibitory effect of GRD-PEI-Bi2O3@PTX-ND nanoparticles combined with radiotherapy on the proliferation of A549 cells

[0180] When the cells are in the logarithmic growth phase, trypsin is used to digest the cells at the bottom of the culture dish, and the cells are resuspended after centrifugation to prepare a cell suspension. The cells are counted using a cell counting plate, with a concentration of 2×10 3The cells were plated into a 96-well plate at a density of 100 cells / well and incubated in a 37°C 5% CO2 incubator for 24 h. Then, different concentrations (0, 0.05, 0.1, 0.2, 0.4, 0.8, 1.6 ug / mL) of GRD-PEI-Bi2O3@PTX-ND nanoparticles were added and cultured for another 24 h. After 24 hours, the 96-well plate was taken out and irradiated with 2Gy of radiotherapy. After 24 hours of radiotherapy, the original culture medium was discarded, and 100 μL of culture medium containing CCK-8 reagent was added to each well (the volume ratio of CCK-8 reagent to RPMI1640 culture medium was 1:9), and then the culture was continued in the incubator for 3 hours. Finally, the absorbance of each group at 450nm was detected by an enzyme marker. The cell survival rate was calculated according to the formula: survival rate = (experimental group-blank control group) / (negative control group-blank control group)×100%, and the obtained data were plotted using Excel 2013 and GraphPadPrismV9.0 software. The results are shown in Figure 6 shown.

[0181] from Figure 6 The analysis shows that the GRD-PEI-Bi2O3@PTX-ND nanoparticles prepared in Example 2 can enhance the sensitivity of radiotherapy at a certain concentration (ie, 0.2 ug / mL).

[0182] Colony formation to explore the radiosensitization effect of GRD-PEI-Bi2O3@PTX-ND nanoparticles

[0183] The purpose of this experiment is to understand the effect of the Bi2O3-based material (GRD-PEI-Bi2O3@PTX-ND nanoparticles) loaded with paclitaxel and nintedanib prepared in Example 2 on A549 cell clones. There are four groups: PBS alone group, PBS + radiotherapy group, GRD-PEI-Bi2O3@PTX-ND group, GRD-PEI-Bi2O3@PTX-ND + radiotherapy group. 500 cells were planted in each well of a 6-well plate, and each group was treated as above. Fresh culture medium was replaced 24 hours after treatment, and the culture medium was placed in an incubator for further incubation. After 7 days, the 6-well plate was removed and the original culture medium was discarded. Each well was washed twice with 1×PBS, the cells were fixed with 4% PFA for 30 minutes, and crystal violet was stained for 30 minutes. Finally, it was washed three times with 1×PBS, and the cells were photographed and counted. The data obtained were processed using Excel 2013 and GraphPadPrismV8.0 software. The results are shown in the figure. Figure 7 shown.

[0184] from Figure 7 The analysis showed that compared with the control group, the cell clone formation rate was lower in the radiotherapy combined with BTN group.

[0185] The combined effect of GRD-PEI-Bi2O3@PTX-ND and X-ray promotes the production of intracellular ROS

[0186] The enhanced local absorption of high-energy rays by nanoparticles composed of Bi2O3 atoms with high atomic number, and the cytotoxicity caused by the release of bismuth ions by bismuth atoms after X-ray irradiation, are the main reasons for the radiosensitization of the bismuth-based nanomaterials of the present invention. After X-ray irradiation, the bismuth-based nanomaterials were divided into four groups: PBS alone group, PBS + radiotherapy group, GRD-PEI-Bi2O3@PTX-ND group, and GRD-PEI-Bi2O3@PTX-ND + radiotherapy group. The reactive oxygen species test kit (DCFH-DA kit) was used to detect the reactive oxygen species level in each group. The results are shown in the figure. Figure 8 shown.

[0187] Depend on Figure 8 From the analysis, it can be seen that after X-ray irradiation, tumor cells containing bismuth-based nanomaterials have the highest and brightest fluorescence level, that is, the amount of ROS produced is the largest, indicating that bismuth-based nanomaterials significantly increase the ROS level of tumor cells after X-ray irradiation, and ROS will further destroy the DNA structure and membrane structure of the cells, thereby achieving the purpose of killing tumor cells.

[0188] GRD-PEI-Bi2O3@PTX-ND combined with X-ray promotes cell apoptosis

[0189] A549 cells (1×10 5 After incubation for 6 hours with RGD-PEI-Bi2O3@PTX-ND, cells / well were treated with RGD-PEI-Bi2O3@PTX-ND for 24 hours, irradiated with X-ray, and incubated for another 24 hours. After washing twice with PBS, the cells were trypsinized and collected in a centrifuge tube. The cells were redispersed in AnnexinV binding buffer, stained with AnnexinV and PI for 15 minutes at room temperature, and finally analyzed by flow cytometry. The results are shown in Fig. 9 shown.

[0190] from Fig. 9 The analysis showed that the apoptosis rate of cells in the radiotherapy combined with RGD-PEI-Bi2O3@PTX-ND group was the highest, indicating that bismuth-based nanomaterials significantly improved the apoptosis ability of tumor cells after X-ray irradiation.

[0191] GRD-PEI-Bi2O3@PTX-ND combined with X-ray promotes cell DNA damage

[0192] 1×10 5The cells were plated into confocal dishes at a density of 100 cells / dish and incubated in an incubator at 37°C and 5% CO2 for 24 hours. The cells were divided into four groups: PBS alone group, PBS + radiotherapy group, GRD-PEI-Bi2O3@PTX-ND group, and GRD-PEI-Bi2O3@PTX-ND + radiotherapy group. After that, 0.2ug / mL of GRD-PEI-Bi2O3@PTX-ND nanoparticle solution was added, and the cells were cultured for 24h. After X-ray irradiation, the cells were cultured for 1h and then washed twice with pre-cooled PBS. 0.5mL of 4% paraformaldehyde was added and fixed at room temperature for 10-20 minutes. 0.3% TritonX-100 was added to break the membrane at room temperature for 10-20 minutes, and then rinsed with PBS at room temperature for 3 times, 5min each time. 1mL of 5% BSA incubation buffer (0.5g BSA+10mLPBS) was added to block and incubate at room temperature for 1h. Each group was also added with antibody diluent 1:100-1:200 dilution of γ-H2AX antibody, and incubated in blocking buffer at 4°C overnight. 1mL of PBS was added to wash 3 times. Fluorescent secondary antibody (1:500) was added to each sample and incubated at room temperature for 1h in the dark. 1mL of PBS was added to wash 3 times. DAPI dye was added to each dish for 10min. Finally, immunofluorescence analysis of stained cells was performed using a confocal microscope. The results are as follows Fig.10 shown.

[0193] Depend on Fig.10 It can be seen that the DNA damage of cells treated with GRD-PEI-Bi2O3@PTX-ND+X-Ray group was the most significant, indicating that the material has a very significant radiosensitization effect at the cellular level.

[0194] In summary, the multifunctional dual-targeted self-assembled bismuth oxide radiotherapy sensitizer of the present invention can be used as a radiotherapy sensitizer and a radiation dose enhancer, and has excellent CT contrast effect, catalyzes hydrogen peroxide to produce more oxygen ions, improves the tumor hypoxic microenvironment, and improves the radiotherapy efficacy; and can actively target tumor cell nuclei, and high-energy Auger electrons can kill tumor DNA nuclei at close range to achieve radiotherapy sensitization effect, and also has the functions of chemotherapy drug carrier, nitric oxide (NO) donor, targeted drug, etc.; at the same time, the dual-targeted self-assembled bismuth oxide radiotherapy sensitizer can be used as an excellent radiotherapy sensitizer, effectively enhancing the killing of tumor cells by high-energy rays, and has a high clinical transformation prospect,

[0195] The invention discloses an intravenously injectable dual-targeted self-assembled bismuth oxide radiosensitizer drug, which is a nanoparticle material loaded with paclitaxel and nintedanib nanoparticles and a component that inhibits DNA damage repair. The physical properties of the Bi2O3 metal material bismuth are utilized to improve the sensitivity of radiotherapy and inhibit radiotherapy resistance. The material's advantages in CT imaging and its ability to catalyze hydrogen peroxide to produce oxygen are utilized to achieve an anti-tumor effect of enhanced radiosensitization.

[0196] The present invention also provides a method for preparing a dual-targeted self-assembled bismuth oxide radiotherapy sensitizer drug and its application in anti-tumor treatment. The dual-targeted self-assembled bismuth oxide radiotherapy sensitizer drug of the present invention has the effect of radiotherapy sensitization, and has the advantages of relatively low cost, simple preparation process, good biocompatibility and large loading capacity; it can reduce the toxic and side effects of chemotherapy drugs and nano drugs, and improve the sensitization effect; it can release nintedanib elements to achieve tumor microenvironment immune regulation, control inflammation, reduce the aggregation of macrophages, etc., significantly enhance the infiltration of killer T cells in the tumor lesion area, and slowly release paclitaxel drugs, further block DNA damage response signal conduction, and reduce its repair ability. It has promotion and application value in the field of radiopharmaceutical technology.

[0197] The above embodiments are only preferred embodiments for fully illustrating the present invention, and the protection scope of the present invention is not limited thereto. Any equivalent substitution or change made by a person skilled in the art based on the present invention is within the protection scope of the present invention.

Claims

1. A dual-targeted self-assembly sensitizer, characterized in that: These include DNA repair inhibitors, bismuth-containing compounds, targeting ligands, and tumor organelle targeting ligands.

2. The dual-targeted self-assembly sensitizer according to claim 1, characterized in that: The dual-targeted self-assembly sensitizer can simultaneously target specific molecules in the tumor cell nucleus and the tumor microenvironment, thereby enhancing the selective accumulation of the drug; The specific molecule is selected from at least one of matrix metalloproteinases, vascular endothelial growth factor, integrin and hypoxia inducible factor.

3. The dual-targeted self-assembly sensitizer according to claim 1, characterized in that: The DNA repair inhibitor is selected from at least one of platinum drugs, platinum drug derivatives, platinum drug analogs, platinum drug isomers, platinum drug metabolites, paclitaxel drugs, paclitaxel drug derivatives, paclitaxel drug analogs, paclitaxel drug isomers, paclitaxel drug metabolites, chemotherapy drugs that act on DNA, chemotherapy drug derivatives that act on DNA, chemotherapy drug analogs that act on DNA, chemotherapy drug isomers that act on DNA, chemotherapy drug metabolites that act on DNA, small molecule DNA repair inhibitors, small molecule DNA repair inhibitor derivatives, small molecule DNA repair inhibitor analogs, small molecule DNA repair inhibitor isomers and small molecule DNA repair inhibitor metabolites; and / or, the targeting ligand is selected from at least one of folic acid, folic acid-conjugated antibodies, folic acid-modified nanoparticles, hyaluronic acid, transferrin, linear RGD peptides, cyclized RGD peptides, polymeric RGD structures, RGD variants, monoclonal antibodies, epidermal growth factor, linear NGR peptides, cyclized NGR peptides, modified NGR sequences, EGFR-binding polypeptides, anti-EGFR polypeptides, chimeric peptides and fusion proteins that can bind to EGFR, EGFR-targeted nanoparticles, EGFR-targeted liposomes, EGFR-targeted gold nanoparticles, and EGFR-targeted quantum dots; And / or, the tumor organelle targeting ligand is selected from at least one of TAT, TAT derivatives, TAT fusion proteins and conjugates, mitochondrial penetrating peptides, mitochondrial penetrating peptide derivatives, MPPs-drug conjugates, MPPs-MTS composite peptides, TAT-MTS composite peptides, polyethyleneimine, polyethyleneimine derivatives, polyethyleneimine-nucleic acid complexes, polylysine, polylysine derivatives, polylysine-nucleic acid complexes, lipid derivatives, nucleus targeting peptides and lysosome targeting peptides; And / or, the bismuth-containing compound is selected from at least one of bismuth nitrate, bismuth chloride, bismuth oxide, bismuth phosphate and bismuth sulfate.

4. The dual-targeted self-assembly sensitizer according to claim 3, characterized in that: The platinum drug is selected from at least one of cisplatin, carboplatin, oxaliplatin and nedaplatin; And / or, the taxane-based drug is selected from at least one of paclitaxel, albumin-bound paclitaxel and micellar paclitaxel docetaxel; and / or, the chemotherapy drug acting on DNA is selected from at least one of fluorouracil, capecitabine, gemcitabine, cytarabine and pemetrexed; and / or, the small molecule DNA repair inhibitor is selected from PARP inhibitors; The PARP inhibitor is selected from at least one of olaparib, rucaparib, niraparib and talazoparib; And / or, the RGD variant is selected from one or both of RGDS and RGDV; And / or, the improved NGR sequence is selected from CNGRC; and / or, the EGFR-targeting nanoparticles are selected from polylactic-glycolic acid nanoparticles; And / or, the EGFR-targeted liposome is selected from one or two of paclitaxel and doxorubicin; And / or, the MPPs-MTS composite peptide is selected from one or two of a mitochondrial penetrating peptide and a mitochondrial targeting sequence composite peptide; And / or, the cell nucleus targeting peptide is selected from at least one of a nuclear localization signal peptide and variants thereof; And / or, the lysosome targeting peptide is selected from at least one of a KFERQ sequence peptide and an endoplasmic reticulum targeting peptide, and the endoplasmic reticulum targeting peptide is selected from a KDEL sequence peptide; and / or, the mass ratio of the targeting ligand to the bismuth-containing compound is 5:1 to 20:1; and / or, the mass ratio of the DNA repair inhibitor to the bismuth-containing compound is 1:1 to 1:4; And / or, the mass ratio of the tumor organelle targeting ligand to the bismuth-containing compound is 2:

1.

5. A method for preparing a dual-targeted self-assembly sensitizer according to any one of claims 1 to 4, characterized in that: The following steps are involved: dispersing a bismuth-containing compound in an organic solvent to obtain a bismuth-containing solution; dissolving the tumor organelle targeting ligand in an organic solvent to obtain a tumor organelle targeting ligand solution; dissolving a DNA repair inhibitor in an organic solvent to obtain a DNA repair inhibitor solution; dissolving the targeting ligand in an organic solvent to obtain a targeting ligand solution; The bismuth-containing solution is added to the tumor organelle targeting ligand solution to obtain a tumor organelle targeting ligand@bismuth-containing compound nanosheet solution; mixing and dispersing the DNA repair inhibitor solution and the targeting ligand solution to obtain a DNA repair inhibitor-targeting ligand compound solution; The DNA repair inhibitor-targeting ligand compound solution is added into the tumor organelle targeting ligand@bismuth-containing compound nanosheet solution, mixed and dispersed, and rotary evaporated to obtain the tumor organelle targeting ligand-bismuth-containing compound@DNA repair inhibitor-targeting ligand compound.

6. The preparation method according to claim 5, characterized in that: The organic solvent is selected from at least one of an alcohol organic solvent, a halogenated hydrocarbon organic solvent, an ester organic solvent and an alkane organic solvent; And / or, the lipid derivative is selected from at least one of phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, distearoylphosphatidylethanolamine, polyethylene glycol-modified distearoylphosphatidylethanolamine, arginine-glycine-aspartic acid-modified DSPE-PEG, polyethyleneimine-modified DSPE-PEG and cholesterol.

7. The preparation method according to claim 6, characterized in that: The alcohol organic solvent is selected from at least one of methanol, ethanol, isopropanol and butanol; And / or, the halogenated hydrocarbon organic solvent is selected from at least one of chloroform, dichloromethane and carbon tetrachloride; And / or, the ester organic solvent is selected from at least one of ethyl acetate, ethyl butyrate and ethyl formate; And / or, the alkane organic solvent is at least one selected from n-hexane, cyclohexane and petroleum ether.

8. A use of the dual-targeted self-assembly sensitizer according to any one of claims 1 to 4, characterized in that: Application of the dual-targeting self-assembly sensitizer in the preparation of anti-tumor drugs.

9. The use of the dual-targeted self-assembly sensitizer according to claim 8, characterized in that: The tumor is at least one of esophageal cancer, human melanoma, non-small cell lung cancer, human cervical cancer, breast cancer, nasopharyngeal carcinoma and brain glioma.

10. An anti-tumor drug, characterized in that: The invention comprises the dual-targeting self-assembly sensitizer according to any one of claims 1 to 4 and pharmaceutically acceptable auxiliary components.

Citation Information

Patent Citations

  • Anti-tumor long-circulating target liposomes for injections

    CN101327190A

  • Bismuth-based composite nano-material, and tumor diagnosis and treatment application thereof

    CN105770893A

  • Lipid-polyhypoxia radiotherapy sensitizer with targeting and radiotherapy sensitization dual functions

    CN107970447A

  • Photo - chemo composition on the basis of microcapsules with a core -shell structure

    WO2014141289A1